Cyclooxygenase-2 expression in skeletal muscle of knockout mice suffering Duchenne muscular dystrophy

Flavia de Oliveira1, De Oliveira Flavia, Hananiah Tardivo Quintana

  • 1Department of Biosciences, Federal University of São Paulo, UNIFESP, Av Ana Costa 95, Vila Mathias, Santos, SP 11060-001, Brazil.

Insights

Duchenne muscular dystrophy (DMD) in mdx mice leads to increased type I collagen and cyclooxygenase-2 (COX-2) expression in fibrotic lesions. This suggests a link between muscle damage and COX-2 activity in DMD.

Area of Science:

  • Biomedical Science
  • Musculoskeletal Research
  • Inflammation Biology

Background:

  • Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and fibrosis.
  • Cyclooxygenase-2 (COX-2) is an enzyme implicated in inflammation and tissue remodeling, but its role in DMD-associated fibrosis is not fully understood.

Purpose of the Study:

  • To investigate the expression of cyclooxygenase-2 (COX-2) in fibrotic lesions within the gastrocnemius muscle of mdx mice, a model for DMD.
  • To correlate COX-2 expression with collagen deposition and histopathological changes in DMD.

Main Methods:

  • Histopathological analysis of gastrocnemius muscle specimens from control (C57BL/10) and mdx mice using Hematoxylin and Eosin (H&E) staining.
  • Sirius Red staining under polarized light to quantify type I and type III collagen.
  • Immunohistochemistry to assess COX-2 expression in muscle tissue.

Main Results:

  • Mdx mice exhibited significant histopathological alterations, including regenerating muscle fibers.
  • A substantial increase in type I collagen deposition was observed in the muscle tissue of mdx mice compared to controls.
  • DMD induced strong COX-2 immunoexpression, particularly in the intercellular spaces of the affected muscle.

Conclusions:

  • Necrotic and fibrotic lesions in Duchenne muscular dystrophy are associated with increased cyclooxygenase-2 (COX-2) expression.
  • These findings suggest that COX-2 plays a role in the fibrotic process occurring in DMD.
  • Targeting COX-2 may represent a potential therapeutic strategy for managing fibrosis in DMD.